Kommentar zu „Medikamentenfreisetzende Stents bleiben Mittel der Wahl bei koronaren Herzkrankheiten“

• Literatur

• 1 Giacoppo D, Alfonso F, Xu B. et al. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol 2020; 75: 2664-2678
• 2 Cortese B, Di Palma G, Guimaraes MG. et al. Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial. JACC Cardiovasc Interv 2020; 13: 2840-2849
• 3 Reger RV, Farah A, Ohlow MA. et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2022; 296: 1504-1510
• 4 Gao C, He X, Ouyang F. et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): An open-label, randomised, non-inferiority trial. Lancet 2024; 404: 1040-1050
• 5 Niehe SR, Vos NS, Van Der Schaaf RJ. et al. 5-Year Clinical Outcomes of Paclitaxel-Coated Balloon Angioplasty vs DES in Acute MI: The REVELATION Trial. JACC Cardiovasc Interv 2024; 17: 1185-1186
• 6 Schömig A, Dibra A, Windecker S. et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380